Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

I-Mab Biopharma Co., Ltd

http://www.i-mabbiopharma.com/en/

Latest From I-Mab Biopharma Co., Ltd

Hugel Expects Acquisition By GS Consortium Won’t Deter Growth Strategy

Hugel says its longer-term global growth strategy will remain intact after a major acquisition of the Korean medical aesthetics company by a consortium including GS Group.

South Korea M & A

Pfizer To Buy Trillium For $2.26bn In A Hematology Pipeline Play

Pfizer will gain two clinical-stage immuno-oncology assets targeting the SRRPα-CD47 axis that it hopes could reach the market in the 2025-2030 timeframe.

Deals M & A

Antibody COVID-19 Therapies Back in China Spotlight Amid Infection Surge

Chinese developers forge ahead with research into antibody therapies for COVID-19 as coronavirus variants gain a toe-hold in the country.

China Research & Development

Massive Selloff Hits US, HK-Listed China Health Cos, Clouds Sunny Prospects

Both Nasdaq- and Hong Kong-listed shares in Chinese health-related companies have been free falling with heavy volumes, after foreign investors spooked by China's general crackdown on the tech sector rushed to exit. The two-day sell-off shows high uncertainty and investors' anxiety over the regulatory overreach but underlying fundamentals still seem strong.

Financing Companies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Tasgen Biotech
    • Third Venture Biopharma
UsernamePublicRestriction

Register